 Orphazyme AS NASDAQ: ORPH has decided to withdraw its European Marketing Application for arimoclomol for Niemann-Pick disease Type C NPC ahead of a final vote and opinion by the CHMP scheduled for later this month. Todays decision to withdraw the MAA enables us to. 